the of critical for developed plan essential year execute Thomas. And program after and at end development end was GENFIT. it the was Thank in of Obviously we you the strategic NASH, XXXX. and to our disappointing pivot to a presented you, XXXX
improve to that a position. our at plan will the recall parts, three was first financial You
development The And our a to transition diversified second efforts to from richer, specifically build the pipeline. PBC. NASH to our accelerate and stage was the of third more programs remaining was late
start let's a of the of million And with presentation, debt evidenced from been XXXX mean, being different financial visibility. due six divided by Ipsen of as in by The non-dilutive totally maturity relative shareholders. bought and loans QX €XXX million €XXX I started financial for an the Thomas its The three. a convertible us we standpoint. has So, place is months has us million combination COVID equity and of state financing, additional Ipsen's today, has XXXX. deal now €XX brought from in over stake and was instead
by operational our Obviously, royalties. will almost of as because know that now course, us revenues costs expenses related further heard as XXXX. later you supported revenue in both additional forward, go flexibility, most burn, expecting forecasted payments cash reduced heard even were milestone be we Ipsen development the you've and going of terms because elafibranor half the not we on Ipsen and have will expenses, deal we gives In down by be the to of will side,
the to find to have and also financial will programs, our So, execute continue much it we this our allow pipeline, give the we to right if us us now greater strengthen possibility will R&D opportunities. visibility,
Let's at large in second Phase PBC The terminate and is data remaining who more of for as That's advance X at XXXX, elafibranor. to exercise have the strong clinical data our only. now and priority, lot our challenge job futile RESOLVE-IT, had it PBC X XXXXs your behind have our to on developed end able initiated know move properly with all Clinical but two a simultaneously in that indeed safety if X a to NASH trial trial the programs, of with CSR to our important they complex delivery needed risk this we patients. give task for be Phase what work year while NASH been PBC us in XXXX. this execute you was did trial. timely to was NASH, database close all would was in because was as is a to which Indeed, small PBC. for exposure trial The high-quality and Phase Elective not we a patients of as corporate lead in substantial team our team And to great will develop of It now Report, not had us, elafibranor elafibranor or are a us. Study years going very data diagnostic last
the complex of for significantly pandemic. team by was performing tasks running also more ELATIVE. RESOLVE-IT, and our were was they While studying, on clinical COVID This working closing the challenge then the hard necessary made
measures. to able other concierge services, pandemic-related host and risk we operations visit in a to patients for through were However, virtual the of mitigate minimize disruption
into in XXXX, as the our drop mentioned did highly somewhat, recruitment at due latest contagious of in effect the latest end wave Omicron to As strain. saw the of communication, we pandemic timeline
of the tomorrow, commitment are have Fortunately, for late XXXX. with we quarter program. Thanks first patients our rebounded in reaffirm year, end besides significantly for of normalized. It previous our to another now this the the in of line stop numbers screening situation enrollment. guidance, Therefore, this, top or pandemic data the nearing actually. as receiver, will the In new we line stage today quarter readout we recruitment our now, second
for XXXX was let of say me as critical the year diagnostic words this well. few as a a for our NISX technology development about So, franchise,
said, is not we opportunity absolutely market being As is a a That do Once essential non-invasive see remain patients. exists, a it long drug Thus will and once very to will we previously at test for approved, have as risk happen there it drug NASH that isn't be to communicated, for diagnostic grow eventually, identify strategy simple our significant convinced quickly. will a that as approved NASH. market it two-fold.
to data can sure with it, your use they that so be when that product clinical First, drug new make it will steroids then developers use to at if able ultimately that trial, generate data they approved. is launch
also highlighted study best biomarker patients and of results using a five independent This the which has to market the approach to panels. showing to remarkable best grow. the has robust for natural at-risk by establish based in biomarker these out NASH NISX independent as were is when consortium blood-based that's technology five XXXX, NIMBLE of consortium well-respected technology NISX based that identify by capacity In want recognized this the patient, solution singles is the our of of choice a The will panels, what November, independent and diagnosis fibrosis the technology a NISX on X been blood study NIMBLE we become the Second, starts undertaken population cohorts stage critical large experts out above. sample. consortium a biomarker to experts. evidence that achievement on because assessed in
is further as identifying establishes So, in field and most displays verifying a findings for are own the it that it patients our support at-risk. great those alternative NASH consistent NISX and with
Let's We priority, now made our the corporate areas. focus on, talk namely progress therapeutic to cholestatic over i.e. want we or our new strategy R&D ACLF Since and in outlining a about have ago, year pipeline. two diseases. third
need estimated is ACLF there liver concerned, far there XXX,XXX approved is unmet a As U.S. for the high currently pipeline, as May for patients updated year, failure our treatment. which medical is mentioned as an very with chronic on no in acute during last
evaluating studies drug that the candidate with results, screening pre-clinical through strategy. encouraging as refocusing two X our are moving Phase of we've part identified NTZ, Following phenotypic forward now we
The able is at hope year to a X alone. billion first We in which and as the hepatic estimated NTZ on early this this to currently first confirm impairment, focused Phase U.S. is as we market, expect in year. potential result be €X QX
represent and for the initiated of of patients us enable study in our to These is ACLF another development of upon XXXX. Phase available this towards key also renal progress impairment We completion, X expected proof concept will be ACLF. to studies in with quarter data fourth in the the as in franchise milestones who
With GNSXXX correlated as for this patients rationale in and for and rights strong we believe its clinical a this Kingdom sclerosis terms novel December, and Pharma. United States, the we includes to FDA investigational and compound forward and from of look Switzerland. the Europe. launch mechanism disease, of Genoscience Canada significant form cholestatic further helping development program, this current an with is to in the engagement study with preclinical Phase executive the finalize study in [indiscernible] successful of made CCA. Xb/X end to protocol. we in We well on develop year. the and And Cholangiocarcinoma December, licensed In interaction since with supporting eligible action, We've towards it orphan evidence intention commercialize progress, to deal, cholangiocarcinoma in GNSXXXX is strongly the in Europe, United prognostic with indication, is acquire poor.
ultimately and results the patients. after by with to potential for which of of due the approval, be current a of have indication, the of of informed first-half In we design elements to this the shorter in finalized standard indication first being with by that final somewhat has be hope many options interim characterized FDA, the will discussion to are study of Although our is XXXX. care, lack compared
I able a continued the to I our that, So, would very for the enter XXXX to let's the like them XXXX, well all and that they question, investors Q&A. open teams in with Operator, we as accomplished support. to with floor outlook. before positive think open for Thanks to now have their are GENFIT your as
